Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Onconano Medicine Inc. operates in the Biotechnology & Pharmaceuticals technology area. The portfolio has 2 pending office actions. These actions are assigned to 2 distinct examiners. The prosecution activity spans 2 distinct art units. This indicates that each pending application is being reviewed by a different examiner in a different technical group, showing technical variety within the company's biotechnology filings.
The busiest examiner is SONG, JIANFENG, who is currently managing 1 pending office action. This 1 action is a portion of the 2 total pending office actions. Since the number of distinct examiners is 2 and the number of distinct art units is 2, the workload is distributed across different officials and departments. Practitioners must address the specific requirements of SONG, JIANFENG and the other examiner in their respective art units. This decentralized structure means that the outcome of one application may not influence the other. The 2 actions are technically independent and represent the entire active workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
| WESTERBERG, NISSA M | 1 | 23.4% | +37.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18502783 | PROTONATED pH RESPONSIVE POLYMER ENCAPSULATION OF BISPECIFIC ANTIBODIES AND CYTOKINES | SONG, JIANFENG | — |
| 17756190 | PH RESPONSIVE COMPOSITIONS, FORMULATIONS, AND METHODS OF IMAGING A TUMOR | WESTERBERG, NISSA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18502783 | PROTONATED pH RESPONSIVE POLYMER ENCAPSULATION OF BISPECIFIC ANTIBODIES AND CYTOKINES | SONG, JIANFENG | — |
| 17756190 | PH RESPONSIVE COMPOSITIONS, FORMULATIONS, AND METHODS OF IMAGING A TUMOR | WESTERBERG, NISSA M | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18502783 | PROTONATED pH RESPONSIVE POLYMER ENCAPSULATION OF BISPECIFIC ANTIBODIES AND CYTOKINES | SONG, JIANFENG | 1675 | §103§112Other | Non-Final OA | — | Pending | Nov 06, 2023 |
| 17756190 | PH RESPONSIVE COMPOSITIONS, FORMULATIONS, AND METHODS OF IMAGING A TUMOR | WESTERBERG, NISSA M | 1618 | §103DPOther | Final Rejection | — | Pending | May 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial